注射用的糖尿病和减重药物（GLP-1受体激动剂）可能诱发胰腺炎和囊肿。
原始表述
وأدوية السكري والتخسيس المحقونة قد تُحدث التهاب البنكرياس والأكياس.
非原话——为转述. 译文由本项目提供；以阿拉伯语原文为准。
译文
注射用的糖尿病和减重药物（GLP-1受体激动剂）可能诱发胰腺炎和囊肿。
出处
- 来源状态
- 档案网站引语（未注明出处）
- 归属
- Elawady (archive paraphrase; source video not given)
- 出处
- https://eltayebat.com/rule/oral-diabetes-drugs/
- 归属的不确定性
- The archive attributes this text to Dr. Diaa in its 'د. ضياء يقول' box but gives no video reference. Transcript check (the project's research files, keyword search of 307 archive transcripts): found_close_paraphrase. GLP-1-based injectables ('gliptins', Mounjaro, Victoza) causing pancreatitis and a cyst 'stuck to the pancreas' are found in 0pG3-_Gr3eA.
- 所声称的健康影响
Acute pancreatitis; cysts
- 涉及人群
Users of GLP-1 receptor agonists
- Elawady 设定的地域限制
none found
来源版本存在差异
يعمل السودو سيست اللي يعمل كيس لازق في البنكريس ده التهاب مزمن وبيعملوا ادويه السكر زي الجليبتس والمونجارو والفيكتوزا والحاجات الحقن دي كل دول يعملوا التهاب بنك كرياس اسمع ركز مع ودانك اسمع الكلمتين
Injectable diabetes drugs such as gliptins, Mounjaro and Victoza all cause pancreatitis; pancreatic pseudocysts are a form of chronic inflammation.
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- Dr Diaa Al Awady د ضياء العوضي is live! (打开来源)
- 发布日期
- 2025年8月10日
- 时间戳
- 0:43:16 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
科学评估
不明确 / 证据不足 – 现有数据无法支持任何方向的评估。
证据确定性: 低 – 进一步研究很可能大幅改变该评估。
1. 说法是什么？
GLP-1 injections cause pancreatitis and cysts.
2. 哪些内容可证实是正确的？
An administrative US case-control study found adjusted OR 2.24 for current GLP-1-based therapy use (A-ODD-14). Product labels warn about pancreatitis; ADA 2026 notes that 'acute pancreatitis has been reported, but causality has not been established' (I-ODD-16). GLP-1 receptor agonists frequently cause gastrointestinal adverse effects (A-ODD-15, I-ODD-07).
3. 哪些内容是错误或夸大的？
A meta-analysis of three long-term blinded RCTs with adjudicated pancreatitis (9,347 vs 9,353 patients) found no increased risk (Peto OR 0.745) (I-ODD-11); in LEADER acute pancreatitis was not increased with liraglutide (18 vs 23 cases) (I-ODD-06); in SAVOR-TIMI (DPP-4 inhibitor) pancreatitis rates were similar (A-ODD-08). The case-control study had strong confounding: cases had far more gallstones, alcohol use, hypertriglyceridaemia and obesity (A-ODD-14). No evidence was found for 'cysts'; LEADER did not assess pancreatic cysts.
4. 哪些内容仍不明确？
Whether a very small absolute increase in pancreatitis exists; trial sequential analysis suggested more evidence is needed (I-ODD-11). LEADER recorded more pancreatic carcinomas with liraglutide (13 vs 5; p=0.06) and more acute gallstone disease (3.1% vs 1.9%; p<0.001), a known cause of pancreatitis; the trial neither confirms nor excludes pancreatic neoplasia (I-ODD-06).
5. 哪些研究支持该说法？
A-ODD-14 (case-control OR 2.24, confounded); I-ODD-113 (meta-analysis of 62 mostly short RCTs: RR 1.44, 1.09-1.89, not significant within strata); label warnings and ADA 2026 (I-ODD-16).
6. 哪些研究与该说法相矛盾？
I-ODD-11 (adjudicated outcome trials: Peto OR 0.745), I-ODD-112 (8 outcome trials, 60,080 patients: no increase in pancreatic adverse effects), I-ODD-06 (LEADER 18 vs 23 cases), A-ODD-08. No study links GLP-1 RAs to pancreatic cysts.
7. 对德国和欧洲而言情况如何？
Same EU labelling.
8. 关于埃及的已知情况是什么？
GLP-1 RAs for weight loss are increasingly used, partly obtained without prescription; supervision is advisable.
9. 合理的实际结论是什么？
使用GLP-1受体激动剂治疗期间出现剧烈而持续的腹痛，需要就医评估；现有证据并未显示存在明确的、有因果关系的胰腺炎风险。
评估详情
- 证据确定性的依据
Observational studies show associations (OR about 2 in a US claims case-control study), labels carry warnings, but meta-analysis of large blinded RCTs found no increase (Peto OR 0.745, 95% CI 0.47-1.17). 'Cysts' is not specified; no evidence was found linking GLP-1 RAs to pancreatic cysts. The word 'can' makes the claim weak; a rare effect cannot be ruled out.
- 来源质量
Archive paraphrase without video reference.
- 地区可推广性
Universal.
- 个体例外情况
History of pancreatitis or gallstone disease increases baseline risk; rapid weight loss raises gallstone risk.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
缺乏高质量证据支持 – 没有良好证据支持该说法；但仅凭这一点并不能证明它是错误的。
研究问题: Do GLP-1 receptor agonists increase the risk of acute pancreatitis and pancreatic cysts?
研究问题详解 (PICO)
- 人群
- People with type 2 diabetes or obesity
- 干预或暴露
- GLP-1 receptor agonists (and tirzepatide)
- 对照
- Placebo or other drugs
- 地域范围
- universal biology
- 结局指标
- Acute pancreatitis
- Pancreatic cysts / cystic neoplasms
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
Pooled trials hint at slightly more pancreatitis with GLP-1 drugs
Meta-analysis of 62 RCTs found a small increase in pancreatitis.
- 实际结果
- RR 1.44 (1.09-1.89); not significant in either stratum by background medication.
- 方法学质量
- moderate (fixed effect, mixed definitions, short trials)
- 相关性
- direct for pancreatitis; nothing on cysts
- 局限
- Methodological weaknesses.
GLP-1 drugs and pancreatitis in US claims
Singh S et al.. JAMA Intern Med 2013 · PMID 23440284 · DOI 10.1001/jamainternmed.2013.2720 病例对照研究已核查摘要US claims case-control study: current GLP-1-based therapy associated with hospitalisation for pancreatitis.
- 实际结果
- Adjusted OR 2.24.
- 方法学质量
- low (strong confounding)
- 相关性
- direct
- 局限
- Cases had more gallstones, alcohol use, hypertriglyceridaemia.
哪些证据不支持该说法？
GLP-1 drugs and pancreatitis in trials
Meta-analysis of three large blinded trials with adjudicated pancreatitis found no increase.
- 实际结果
- Peto OR 0.745 (0.47-1.17).
- 方法学质量
- high
- 相关性
- direct
- 局限
- Imprecise for small effects.
GLP-1 injections in 60,080 people: fewer deaths, no more pancreas problems
Sattar N et al.. Lancet Diabetes Endocrinol 2021 · PMID 34425083 · DOI 10.1016/S2213-8587(21)00203-5 Meta分析已核查摘要新增Meta-analysis of 8 outcome trials (60,080 patients): no increase in pancreatic adverse effects.
- 实际结果
- No increase reported; death HR 0.88.
- 方法学质量
- high
- 相关性
- direct
- 局限
- Pancreatitis numbers not in abstract.
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Large blinded outcome trials with adjudicated events show no clear increase in pancreatitis; a pooled analysis of many smaller trials suggests a small relative increase of a rare event. A rare effect cannot be excluded, which is why labels advise stopping the drug if pancreatitis is suspected. No evidence was found that GLP-1 RAs cause pancreatic cysts; only two case reports and expert reviews on use in people who already have cystic neoplasms were found.
为什么有些研究权重更大
Adjudicated outcome trials weigh more than investigator-reported events in short trials and confounded claims data.
因果关系是否已确立？ 尚未确立 ADA 2026: pancreatitis reported but causality not established.
仍存在的不确定性
Whether a very small absolute increase exists; effects in people with gallstones.
合理的结论
Pancreatitis is a possible rare effect that is not proven; the 'cysts' part is unsupported.
为什么研究结果看起来互相矛盾？
Wen 2025 (RR 1.44) and outcome-trial meta-analyses (no increase) differ in trial selection (short trials with variable pancreatitis definitions and fixed-effect pooling vs large adjudicated trials). They are compatible with, at most, a small relative increase in a rare event.
这是否取决于国家？
- 一般生物学效应
- Drug pharmacology and physiology are universal.
- 饮食习惯
- Prolonged fasting, Ramadan fasting and very-low-carbohydrate eating change the risk of hypoglycaemia and ketoacidosis with some drugs; relevant in Egypt and among Muslims in Europe.
- 食品原产地
- Not applicable.
- 污染物
- Not applicable.
- 本国生产条件
- Not applicable (same active substances; generics widely used in Egypt).
- 法律规则
- Drug labels and warnings are set by FDA/EMA and national regulators; Egyptian labelling not reviewed.
- 实际监测数据
- No Egypt-specific pharmacovigilance data were found for this outcome.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- CI symmetry; pooled vs subgroup significance – All CIs symmetric; significant pooled estimate with non-significant strata reflects reduced power. 已重新计算
- LEADER absolute difference in pancreatitis – 0.39% vs 0.49%: -0.11 percentage points (CI -0.37 to 0.16). 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Acute pancreatitis with GLP-1 RAs vs placebo
- 起始等级
- 高（随机试验）
- 降级理由
- inconsistency (outcome trials vs pooled smaller trials)
- imprecision (rare events)
- 结果
- 低
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- ADA: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (Diabetes Care 2026;49 Suppl 1) (2026) · 原始文献
Pancreatitis: acute pancreatitis has been reported, but causality has not been established; do not initiate if at high risk; discontinue if suspected. Avoid incretin drugs in people with a history of pancreatitis.
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| PubMed | 2026年10月26日 | ("GLP-1 receptor agonist*"[tiab] OR semaglutide[tiab] OR liraglutide[tiab] OR tirzepatide[tiab] OR incretin*[tiab]) AND pancreatitis[ti] AND (meta-analysis[pt] OR systematic review[pt]) AND 2021:2026[dp] | 双向 | 5 | |
| PubMed | 2026年10月26日 | ("GLP-1"[tiab] OR incretin[tiab] OR semaglutide[tiab] OR liraglutide[tiab] OR exenatide[tiab]) AND ("pancreatic cyst*"[tiab] OR "intraductal papillary"[tiab] OR IPMN[tiab]) | 支持性证据 | 9 | |
| PubMed | 2026年10月26日 | Sattar N[au] AND "GLP-1 receptor agonists"[tiab] AND meta-analysis[ti] AND 2021[dp] | 反对性证据 | 2 | |
| ADA Standards of Care 2026, Section 9 (PubMed Central) | 2026年10月26日 | Fetched https://pmc.ncbi.nlm.nih.gov/articles/PMC12690185/; Table 9.2 safety statements. The diabetesjournals.org DOI landing pages returned HTTP 403; the identical article was read in PubMed Central. | 指南 | 1 |
待解决的问题
Long-term pancreatic safety with high-dose obesity treatment; effect in people with existing cystic lesions.
核查深度如何？
8 项相关研究：3 项核查了全文（其中 1 项进行了结构化偏倚风险评估），5 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
评定结论的变更历史
- 2026年10月25日 · 第 1 阶段 · 初始评估: 不明确 / 证据不足 (低)
- 2026年10月26日 · 第 4 阶段（系统证据审查） · 在扩展证据后重新审查；评定结论不变: 不明确 / 证据不足 (低)
A new RCT meta-analysis (I-ODD-113) adds modest support for a small pancreatitis increase, while the outcome-trial meta-analysis (I-ODD-112) supports no increase; the balance remains uncertain. No evidence for cysts was found.
新来源: I-ODD-112 I-ODD-113
通俗解释
一些数据库研究提示，GLP-1注射剂可能引起胰腺发炎，但大型随机对照试验并没有发现其病例比安慰剂组更多。医生仍然会提醒患者，如出现剧烈腹痛应及时报告。没有证据表明这些药物会引起囊肿。
与该说法相关的研究
支持该说法的研究 (2)
-
GLP-1 drugs and pancreatitis in US claims
Singh S et al.. JAMA Intern Med 2013 · PMID 23440284 · DOI 10.1001/jamainternmed.2013.2720病例对照研究被 Tayebat 档案网站引用已核查摘要Users had about twice the odds of pancreatitis, but they also had more risk factors.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
GLP-1-based therapies and acute pancreatitis
- 研究是如何开展的？
Population-based matched case-control (US claims)
- 研究了多少人、动物或样本？
1,269 cases, 1,269 controls; Adults 18-64 with type 2 diabetes
- 实际发现了什么？
aOR 2.24.
- 观察到的效应有多大？
aOR 2.24 (1.36-3.68)
- 研究结果对日常生活意味着什么？
Signal not confirmed in trials.
- 该研究有哪些局限？
Strong confounding; Claims data
- 它对 Elawady 的具体说法说明了什么？
Supports C-ODD-04.
- 研究结果是否适用于德国和欧洲？
US data.
- 从该研究中明确不能得出什么结论？
Causation.
-
Pooled trials hint at slightly more pancreatitis with GLP-1 drugs
Wen J et al.. Endocrinol Diabetes Metab 2025 · PMID 40988099 · DOI 10.1002/edm2.70113Meta分析独立交叉核查已核查全文★ 关键研究RR 1.44 overall, but not significant in subgroups; events rare.
RR 1.44 for pancreatitis; no data on cysts.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Assess pancreatitis and pancreatic cancer in GLP-1 RA trials.
- 研究是如何开展的？
Meta-analysis of 62 RCTs.
- 研究了多少人、动物或样本？
66,232 patients.
- 实际发现了什么？
Small overall increase in pancreatitis; no overall increase in pancreatic cancer.
- 观察到的效应有多大？
RR 1.44 (1.09-1.89).
- 研究结果对日常生活意味着什么？
If there is an extra risk, it is small; severe abdominal pain should be checked.
- 该研究有哪些局限？
Fixed-effect model, mixed definitions, short trials.
- 它对 Elawady 的具体说法说明了什么？
Partly supports 'can trigger pancreatitis'; no support for cysts.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
That GLP-1 RAs cause pancreatic cysts.
该组中没有被标记为关键研究的研究。
与该说法相矛盾或限制该说法的研究 (3)
-
GLP-1 drugs and pancreatitis in trials
Storgaard H et al.. Diabetes Obes Metab 2017 · PMID 28105738 · DOI 10.1111/dom.12885Meta分析独立交叉核查已核查摘要In large blinded trials, pancreatitis was not more frequent with GLP-1 drugs than placebo.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
GLP-1 RAs and acute pancreatitis
- 研究是如何开展的？
Systematic review and meta-analysis of long-term placebo-controlled RCTs with adjudicated pancreatitis
- 研究了多少人、动物或样本？
3 RCTs; 9,347 vs 9,353; Type 2 diabetes
- 实际发现了什么？
OR 0.745 (n.s.).
- 观察到的效应有多大？
Peto OR 0.745 (0.47-1.17)
- 研究结果对日常生活意味着什么？
No clear pancreatitis risk.
- 该研究有哪些局限？
Only 3 trials; Rare outcome
- 它对 Elawady 的具体说法说明了什么？
Contradicts C-ODD-04.
- 研究结果是否适用于德国和欧洲？
Multinational trial including European sites or directly applicable to EU practice.
- 从该研究中明确不能得出什么结论？
Exclude very small risk.
-
Saxagliptin heart safety trial
Scirica BM et al.. N Engl J Med 2013 · PMID 23992601 · DOI 10.1056/NEJMoa1307684随机对照试验被 Tayebat 档案网站引用已核查摘要No effect on heart attacks or strokes, but more heart failure hospitalisations (3.5% vs 2.8%, i.e. 0.7 percentage points).
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
CV safety/efficacy of saxagliptin
- 研究是如何开展的？
Double-blind placebo-controlled CV outcome RCT (SAVOR-TIMI 53)
- 研究了多少人、动物或样本？
16,492; Type 2 diabetes with or at risk for CV events
- 实际发现了什么？
HR 1.00 primary; HF HR 1.27.
- 观察到的效应有多大？
HR 1.27 HF
- 研究结果对日常生活意味着什么？
Avoid saxagliptin in heart failure risk.
- 该研究有哪些局限？
Short follow-up; Industry funded
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
Multinational/US/UK data; transferable to EU practice.
- 从该研究中明确不能得出什么结论？
Class-wide harm.
-
GLP-1 injections in 60,080 people: fewer deaths, no more pancreas problems
Sattar N et al.. Lancet Diabetes Endocrinol 2021 · PMID 34425083 · DOI 10.1016/S2213-8587(21)00203-5Meta分析独立交叉核查已核查摘要★ 关键研究Death HR 0.88; MACE HR 0.86; no increase in pancreatic adverse effects.
No increase in pancreatic adverse effects in 8 outcome trials.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Pool GLP-1 RA outcome trials.
- 研究是如何开展的？
Meta-analysis of 8 RCTs.
- 研究了多少人、动物或样本？
60,080 patients.
- 实际发现了什么？
Benefits on heart, kidney and survival; no pancreatic safety signal.
- 观察到的效应有多大？
MACE -14%, death -12%.
- 研究结果对日常生活意味着什么？
In large trials these drugs prolonged life and did not cause more pancreatitis.
- 该研究有哪些局限？
Exact pancreatitis numbers not in abstract.
- 它对 Elawady 的具体说法说明了什么？
Contradicts a clear pancreatitis risk and net harm.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
Very rare effects.
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (3)
-
Stomach and bowel side effects of weight-loss injections
Sodhi M et al.. JAMA 2023 · PMID 37796527 · DOI 10.1001/jama.2023.19574队列研究被 Tayebat 档案网站引用已核查摘要Not verified (no abstract).
该研究是否支持这一具体说法？ 不明确 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
GI adverse events with GLP-1 RAs used for weight loss (per title)
- 研究是如何开展的？
Research letter; retrospective cohort (no abstract in PubMed; full text could not be retrieved)
- 研究了多少人、动物或样本？
not verifiable; not verifiable
- 实际发现了什么？
Not verified.
- 观察到的效应有多大？
not verified
- 研究结果对日常生活意味着什么？
GI side effects are common with GLP-1 RAs (RCTs).
- 该研究有哪些局限？
Not read
- 它对 Elawady 的具体说法说明了什么？
Background for C-ODD-04.
- 研究结果是否适用于德国和欧洲？
unknown
- 从该研究中明确不能得出什么结论？
Anything quantitative.
-
ADA guideline 2026: diabetes medicines
American Diabetes Association Professional Practice Committee for Diabetes*. Diabetes Care 2026 · PMID 41358900 · DOI 10.2337/dc26-S009指南 / 立场声明独立交叉核查已核查全文★ 关键研究Insulin is essential in type 1 diabetes; SGLT2/GLP-1 drugs are recommended for heart and kidney protection; side effects listed.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Pharmacologic glycaemic treatment
- 研究是如何开展的？
Clinical practice guideline (ADA Standards of Care 2026, Section 9)
- 研究了多少人、动物或样本？
not applicable; People with type 1 and type 2 diabetes
- 实际发现了什么？
See results.
- 观察到的效应有多大？
not applicable
- 研究结果对日常生活意味着什么？
Medicines chosen by benefit-risk.
- 该研究有哪些局限？
Partially read
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
Consistent with ADA/EASD consensus.
- 从该研究中明确不能得出什么结论？
Not applicable.
-
Liraglutide heart trial
Marso SP et al.. N Engl J Med 2016 · PMID 27295427 · DOI 10.1056/NEJMoa1603827随机对照试验独立交叉核查全文，含结构化偏倚风险评估★ 关键研究Fewer heart deaths and deaths overall; pancreatitis not increased, but more gallstone disease and a small, non-significant excess of pancreatic cancer.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
CV outcomes of liraglutide
- 研究是如何开展的？
Double-blind placebo-controlled RCT (LEADER)
- 研究了多少人、动物或样本？
9,340; Type 2 diabetes with high CV risk
- 实际发现了什么？
Heart attack, stroke or heart death 13.0% vs 14.9%; deaths 8.2% vs 9.6%; acute pancreatitis 18 vs 23 patients; pancreatic cancer 13 vs 5 (not significant); gallstone disease 3.1% vs 1.9%.
- 观察到的效应有多大？
HR 0.87; death HR 0.85
- 研究结果对日常生活意味着什么？
This drug class protects heart and/or kidneys in the studied patients.
- 该研究有哪些局限？
Industry funded with sponsor co-analysis; high-risk population; safety outcomes not powered and not adjusted for multiple testing; 3.5-5 years follow-up.
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
Multinational trial including European sites or directly applicable to EU practice.
- 从该研究中明确不能得出什么结论？
Benefit in low-risk people; that pancreatic cancer risk is absent or present (too few cases); anything about pancreatic cysts.
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
Same EU labelling.
埃及
GLP-1 RAs for weight loss are increasingly used, partly obtained without prescription; supervision is advisable.
在我的国家适用什么？
一般科学评估
不明确 / 证据不足 不明确：对事件进行了专门判定的大型试验没有显示胰腺炎明显增加，对较小型试验的汇总分析提示这一罕见事件最多只有小幅增加，而囊肿则没有任何证据。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.. Singh S et al.. JAMA Intern Med 2013 · PMID 23440284 · DOI 10.1001/jamainternmed.2013.2720
- Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.. Wen J et al.. Endocrinol Diabetes Metab 2025 · PMID 40988099 · DOI 10.1002/edm2.70113
- Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes.. Storgaard H et al.. Diabetes Obes Metab 2017 · PMID 28105738 · DOI 10.1111/dom.12885
- Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.. Scirica BM et al.. N Engl J Med 2013 · PMID 23992601 · DOI 10.1056/NEJMoa1307684
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.. Sattar N et al.. Lancet Diabetes Endocrinol 2021 · PMID 34425083 · DOI 10.1016/S2213-8587(21)00203-5
- Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.. Sodhi M et al.. JAMA 2023 · PMID 37796527 · DOI 10.1001/jama.2023.19574
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes*. Diabetes Care 2026 · PMID 41358900 · DOI 10.2337/dc26-S009
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.. Marso SP et al.. N Engl J Med 2016 · PMID 27295427 · DOI 10.1056/NEJMoa1603827